Cardiac biomarkers, such as cardiac troponin T (cTnT), brain natriuretic peptide (BNP), and N-terminal-pro-BNP (NT-pro-BNP), are commonly used to diagnose acute coronary syndrome and congestive heart failure exacerbation in symptomatic patients. Levels of these biomarkers are frequently chronically elevated in asymptomatic patients with ESRD who are receiving maintenance dialysis. Other imaging biomarkers commonly encountered in nephrologists' clinical practice, such as coronary artery calcium measured by computed tomography, left ventricular hypertrophy, and carotid intima-media thickness, are also frequently abnormal in asymptomatic patients with ESRD. This article critically reviews the limited observational data on associations between cTnT, BNP, NT-pro-BNP, coronary artery calcium, left ventricular hypertrophy, and carotid intimamedia thickness with cardiovascular events and death in non-dialysis-dependent patients with CKD. Although sufficient evidence suggests that these biomarkers may be used for prognostication, the diagnostic utility of cTnT, BNP, and NT-pro-BNP remain challenging in patients with CKD. Decreased renal clearance may affect the plasma levels of these biomarkers, and upper reference limits were originally derived in patients without CKD. Until better data are available, higher cutoffs, or a rise in level compared with previous values, have been proposed to help distinguish acute myocardial infarction from chronic elevations of cTnT in symptomatic patients with CKD. Additionally, it is not known whether these biomarkers are modifiable and amenable to interventions that could change hard clinical outcomes in patients with CKD not yet undergoing long-term dialysis.
Introduction
Cardiovascular disease (CVD) is the leading cause of death in patients with CKD and ESRD, accounting for up to 50% of all deaths (1) . Cardiac biomarkers, such as cardiac troponin T (cTnT) and I (cTnI), brain natriuretic peptide (BNP), and N-terminal-pro-BNP (NTpro-BNP), are commonly used for diagnosing acute myocardial infarction (AMI) and congestive heart failure (CHF) exacerbation. However, chronic elevations of cTnT are observed in 80%-90% of asymptomatic patients with advanced CKD and ESRD (2) . cTnT has evolved into an important prognostic factor in dialysis-dependent patients with ESRD, as elevated levels are associated independently with adverse cardiovascular (CV) outcomes (3) . Fewer data describe an association between elevated troponins and CVD in patients with non-dialysis-dependent CKD. Other commonly used circulating and imaging-based cardiac biomarkers are also associated with poor CV outcomes in asymptomatic patients with ESRD, but such associations are less clearly established in CKD.
The first aim of this review is to summarize studies that reported associations between traditional cardiac biomarkers, such as cTnT, BNP, NT-pro-BNP, left ventricular mass index (LVMI), coronary artery calcium (CAC) scores, carotid intima-media thickness (cIMT), and clinical outcomes in patients with CKD not yet undergoing maintenance dialysis in an attempt to highlight strengths and limitations of existing data for prognostication. The second aim is to review data that support the utility of these biomarkers for diagnostic purposes in the acute setting. These specific biomarkers were chosen because they are noninvasive tests commonly used in clinical practice. For each biomarker, a general description is given, followed by discussion of levels in CKD, association with outcomes, and, finally, the clinical utility in patients with CKD. Knowledge gaps are identified and areas for future research suggested.
Cardiac Troponin Levels in CKD
Both cTnI and cTnT are biomarkers of cardiac injury that can be measured with standard assays and highsensitivity (hs) assays, which detect levels about 10-fold lower than the standard assay. However, the upper reference limits for cardiac troponins were originally derived in persons without CKD, and these biomarkers are elevated in up to 80% of patients with asymptomatic CKD and ESRD (2) . Troponin elevation in this context does not necessarily indicate acute ischemia from coronary atherosclerosis but may be due to decreased renal clearance or chronic myocardial injury. The mechanisms for this are multifactorial and include myocardial strain from altered hemodynamics, inflammation, endothelial dysfunction, and subendocardial ischemia (3,4) ( Figure  1 ). The effect of renal clearance on circulating troponin concentrations is uncertain (3) . Previous literature suggested that cTnT levels, compared with cTnI levels, are more commonly elevated in asymptomatic patients with ESRD (5) . Plausible mechanisms for differential elevations include adsorption of cTnI on the dialyzer membrane imparting increased clearance, degradation of the labile cTnI molecule, advanced glycosylation of cTnT imparting decreased clearance, or uremic toxins causing conformational changes in the epitope region and altering the interaction with the assay antibodies (3) . Previous clinical data were heavily influenced by differing sensitivities of the cTnT and cTnI assays and are not relevant to contemporary clinical practice. Consensus guidelines, therefore, do not specify a preference for use of cTnI over cTnT in patients with CKD (4) . cTnT and cTnI provide largely identical information, and selection between them is typically influenced by laboratory equipment and vendor selection. Unlike the cTnT assay produced by a single manufacturer, cTnI assays are produced by multiple manufacturers using different antibody pairs, and assays are not interchangeable across institutions and studies (6) . We therefore chose to focus the following discussion on cTnT.
Higher cutoffs than used in persons without CKD for the diagnosis of AMI were suggested in patients with CKD and ESRD. A cTnT cutoff of 350 ng/L (.10-fold higher than the recommended cutoff for general use) had the best sensitivity (95%) and specificity (97%) for AMI in 284 patients with ESRD presenting with chest pain (7) . In 89 patients with asymptomatic CKD stages 3-5, the 95th percentile for hscTnT was 139 ng/L, .10-fold higher than that derived in the general population (8) , with levels increasing across higher CKD stages. Another study reported that the specificity of a cutoff of .14.0 ng/L, as recommended for diagnosis of AMI in the general population, was much lower in those Figure 1 . | Cardiac troponins in patients with CKD. In response to injury, including altered hemodynamics, inflammation, and endothelial dysfunction, cardiac myocytes release troponin T (cTnT) and troponin I (cTnI) into the circulation from the troponin I-troponin T-troponin C (troponin I-T-C) complex present on the thin filament of the contractile apparatus. Serum cTnI and cTnT levels are measured by electrochemiluminescence immunoassay (ECLIA). Compared with cTnI, cTnTassays are standardized. In addition, several reasons explain why serum cTnT, compared with cTnI levels, are elevated in asymptomatic patients with ESRD. In asymptomatic patients with CKD, cardiac troponin levels are associated with various surrogate and hard clinical outcomes.
with an eGFR of #60 ml/min per 1.73 m 2 (54%) versus .60 ml/min per 1.73 m 2 (87%) (9). A higher cutoff of .43.2 ng/L had a much higher specificity (88%) in those with an eGFR#60 ml/min per 1.73 m 2 . In addition to higher cutoffs, a rise in troponins compared with previous chronically elevated values, or a rise and/or fall using serial measurements, has been proposed to help distinguish AMI from chronic elevations of cTnT in patients with advanced CKD or ESRD (4, 10, 11) .
Cardiac Troponins and Surrogate Outcomes
cTnT levels were associated with CV events and all-cause mortality in asymptomatic patients with ESRD (12) . Although fewer data extend similar associations to patients with nondialysis CKD, several studies reported correlations between cTnT or hs-troponin T (hs-cTnT) with surrogate and hard outcomes (Table 1) (2, (13) (14) (15) (16) (17) (18) (19) (20) . Cross-sectional studies revealed an association between higher cTnT and decreased eGFR, as well as measures of left ventricular hypertrophy (LVH). An analysis of the Chronic Renal Insufficiency Cohort (CRIC) reported detectable hs-cTnT ($3 ng/L) among 81% (Table 1 ) (2). hs-cTnT was associated with higher LVMI across all LVMI categories, and lower ejection fraction, mainly in the lowest category (#35%) (2). In another crosssectional report from CRIC, the highest quartile of hs-cTnT (.24 ng/L) compared with undetectable levels was associated with the presence of LVH and left ventricular systolic dysfunction (LVSD) (21) . Among asymptomatic outpatients with CAD and eGFR,60 ml/min per 1.73 m 2 , elevated hs-cTnT was associated with higher LVMI, lower creatinineand cystatin-based eGFRs, and higher urine albumin-tocreatinine ratio (UACR) ( Table 1) (17) . Correlations between cTnT and eGFR were confirmed in British outpatients with atherosclerotic renovascular disease (16) . A Japanese study of nondiabetic patients with CKD reported that those with echocardiographic evidence of left ventricular diastolic dysfunction (LVDD) had a significantly higher hs-cTnT level than those without (19) .
Cardiac Troponins and Hard Outcomes
Limited prospective data are available regarding the association of cTnT with CV outcomes in nondialysis patients with CKD. In a British study, cTnT was detectable ($10 ng/L) in 43% of asymptomatic patients with CKD stages 3-5 (13). Detectable cTnT was associated with increased all-cause mortality at 19 months ( (14) . Given low event rates, however, these studies were limited by lack of multivariable analysis and adjustment for confounders (13, 14, 16) . More recently, reports from larger cohorts showed an independent association between hs-cTnT and CV events among patients with CKD in adjusted analyses (Table 1) (15, 18) .
Clinical Utility of Cardiac Troponins in CKD
In summary, because troponin upper reference limits were originally derived in non-CKD samples, knowledge gaps exist in establishing consensus regarding appropriate diagnostic cutoff values in patients with CKD, as well as the required magnitude of the threshold of change in serial values. The updated consensus definition of AMI requires a rise and/or fall in serial levels, with at least one value above the 99th percentile of the upper reference limit, in addition to appropriate electrocardiographic changes, imaging consistent with myocardial damage, or new regional wall abnormalities (4). However, it does not specify different thresholds for defining AMI in patients with CKD. Nonetheless, it seems reasonable to consider higher threshold values in patients with CKD or rely more heavily on assessment of serial changes to confirm AMI diagnosis. There are no recommendations to support a specific threshold of change in patients with CKD, although recent data in 19 patients with ESRD support the use of a $20% change for hs-cTnT (10,11) a value that exceeds analytical variation alone (6) . For prognostic purposes, it appears that detectable compared with undetectable troponins portend higher risk for future death and CV events. Future research needs to ascertain whether further work-up or intervention is warranted when clinicians find a detectable troponin in asymptomatic patients with CKD.
BNP and NT-pro-BNP in CKD
NT-pro-BNP and BNP are commonly tested in symptomatic patients suspected of acute CHF exacerbation. In one study, they were elevated in 56% of asymptomatic patients with CKD (22) . Pre-pro-BNP is synthesized within the cardiac myocytes in response to ventricular wall stress and stretch (23) . After removal of a signaling peptide within the cytosol, pro-BNP is further cleaved into the inactive form (NT-pro-BNP) and the active hormone (BNP) at the time of release from the myocyte or in the circulation ( Figure  2 ). NT-pro-BNP is more stable, with a longer half-life, and may be a better biomarker for chronic volume expansion or stress than is BNP (23) . Reduced renal function decreases the fractional plasma clearance of both BNP and NT-pro-BNP, and studies reported correlations between graded elevations in these peptides and declining eGFR or advancing CKD stages (Table 2) (22, (24) (25) (26) (27) (28) (29) (30) (31) (32) . The clearance of NT-pro-BNP is predominantly renal, while BNP is also degraded systemically ( Figure 2 ) (23) . This may explain the observed correlation of reduced eGFR to a greater extent with NT-pro-BNP than with BNP (23, 24) , and the increased ratio of NT-pro-BNP/BNP with advancing CKD stages (30), a finding not borne out by all studies. One study reported an equal dependence on renal clearances for both peptides, although most participants had a GFR$30 ml/min per 1.73 m 2 (33) , suggesting that clearance may be similar for both until renal function deteriorates to advanced stages.
BNP and Surrogate Outcomes in CKD
Elevated levels of both BNP and NT-pro-BNP are associated with abnormal echocardiographic findings in patients with CKD (Table 2) (20, 24, 31, 32, 34) . Among those with eGFR,60 ml/min per 1.73 m 2 , LVMI positively correlated with BNP and NT-pro-BNP levels (24) . NT-pro-BNP was independently associated with presence of LVSD in patients with CKD (31) ( Table 2 ). Higher gradations in NT-pro-BNP cutoffs to detect LVSD were reported for increasing CKD stages (31) . A Chinese study showed that LVDD positively correlated with Log-NT-pro-BNP (32) ( Table 2 ). In the CRIC study, the highest compared with lowest quartile of NT-pro-BNP was associated with a 3-fold higher odds of LVH and LVSD (20) ( Table 2) .
BNP and Hard Outcomes in CKD
BNP and NT-pro-BNP are also associated with hard outcomes in CKD (Table 2 ). In a Japanese study, both BNP and NT-pro-BNP were associated with death and the composite of death and CV events. On the basis of the areas under the curve, the authors concluded that NT-pro-BNP may be a superior marker to BNP for composite events in patients with CKD stages 4 and 5 (versus stages 1-3), although a formal statistical test was not used to determine whether the curves significantly differed (26) . Among the African American Study of Kidney Disease and Hypertension cohort, those with elevated NT-pro-BNP had a four times higher hazard for CV events than those with undetectable levels (Table 2) (35). The association was significantly stronger in those with than without proteinuria (interaction P=0.05) (35) . In Chinese patients with known CAD, NT-pro-BNP was associated with all-cause death if eGFR was ,60 ml/min per 1.73 m 2 (36) . In addition, the NT-pro-BNP cutoff associated with mortality was higher in patients with CKD (2584 pg/ml) than in persons without CKD (370 pg/ml) (36) . Several other studies reported similar associations between NT-pro-BNP, CV events, and all-cause death (Table 2) (37-39).
Clinical Utility of NT-pro-BNP and BNP in CKD
To summarize, NT-pro-BNP and BNP can be used for prognostication in patients with CKD because elevated levels are associated with both adverse surrogate and hard outcomes in this population. However, most studies Figure 2 . | Brain natriuretic peptides in patients with CKD. In response to increased stretch or tension, left ventricular myocytes release brain natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP) from precursors. BNP is an active molecule with a short plasma half-life and is degraded in the circulation by enzymatic action. NT-pro-BNP is the inactive form of BNP, with a longer half-life. It is primarily cleared by the kidneys. Reduced eGFR correlates to a greater extent with elevated plasma NT-pro-BNP than to BNP levels. Increased NT-pro-BNP/BNP ratio correlates with advancing CKD stages, especially if the eGFR is ,30 ml/min per 1.73 m 2 . However, both BNP and NT-pro-BNP are associated with surrogate and hard clinical outcomes in asymptomatic patients with CKD. 
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Cross-sectional Korean predialysis CKD, outpatients or from emergency department NT-pro-BNP associated with LVSD independent of eGFR; higher NT-pro-BNP cutoffs for worse CKD stages: 2165 pg/ml in CKD 3, 4740 pg/ml in CKD 4, and 15,892 pg/ml in CKD 5
Yang et al. 
CAC in CKD
CAC as measured by computed tomography is a noninvasive measurement of the burden of coronary atherosclerosis. Patients with CKD have higher CAC scores compared with age-matched controls without CKD, and patients with CKD without baseline calcification exhibit higher incidence rates of developing future de novo CAC (41, 42) . Cross-sectional analyses have reported a graded relationship between lower eGFR and increasing CAC (41) . These associations were attenuated after adjustment for traditional CV risk factors, such as diabetes, but remained statistically significant for patients with an eGFR,30 ml/min per 1.73 m 2 (42). It is not entirely clear whether a decline in eGFR plays a mechanistic role for developing de novo CAC and CAC progression. Interestingly, several analyses reported higher baseline CAC and CAC progression to be associated with eGFR decline and worsening proteinuria (43) (44) (45) (Table 3) . A plausible explanation may be that the progression of CAC and CKD are collinear because of the presence of similar risk factors for both disease processes.
Both traditional and nontraditional CV risk factors are associated with the presence and severity of CAC in patients with CKD who are not undergoing dialysis. Traditional factors explored included advanced age, white race, male sex, higher body mass index, and diabetes mellitus, in particular (46) (47) (48) . A retrospective study of patients with stages 2-5 CKD with well controlled BP reported higher prevalence of CAC in patients with diabetes than in nondiabetic patients (77% versus 33%) ( Table 3 ) (46), and another study found faster progression in CAC among diabetic patients with CKD than in those without diabetes (48) . We previously reported in a multiethnic, population-based asymptomatic cohort that three nontraditional risk factors-calcium-phosphorus product, homocysteine, and osteoprotegerin-were independently associated with high CAC scores, and diminished the magnitude of the association between the presence of CKD and elevated CAC, suggesting that they may play mechanistic roles in the development of CAC (49) . Others reported similar associations between elevated serum phosphorus and CAC in patients with CKD (48).
CAC and Clinical Outcomes
Fewer data are available on unfavorable clinical implications of CAC in predialysis CKD versus ESRD samples. The few observational studies reporting associations of CAC with adverse outcomes are limited by low event rates, Table 2 . 
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Longitudinal Dutch outpatients, 606 renal transplant recipients NT-pro-BNP, decreased eGFR, and hypertension medication use associated with death in both renal transplant and nontransplant patients AASK, African American Study of Kidney Disease and Hypertension; CHF. congestive heart failure; ACS, acute coronary syndrom; VA, Veterans Affairs; NT-pro-BNP, N-terminal B-type natriuretic peptide; 95% CI, 95% confidence interval; NYHA, New York Heart Association; aHR, adjusted hazard ratio; AUC, area under the curve; aRR, adjusted relative risk. limited follow-up, or ethnic homogeneity (Table 3 ) (46, 47, 50, 51) . A study of a predominantly Latino diabetic cohort reported that those in the highest compared with the lowest quartile of baseline CAC had a higher hazard of all-cause mortality at 39 months (47) . During a 25-month follow-up, there was four times higher risk of CV death or AMI among outpatients with stages 2-5 CKD and baseline CAC scores .100 Agatston units (AU) compared with #100 AU (50) . Finally, in renal transplant recipients, CAC score assessed at the inception of the cohort was associated with the composite of CV death, AMI, stroke, transient ischemic attack, and revascularization at 2.3 years (Table 3 ) (51). However, models were overadjusted for the few events in the last two studies (50, 51) .
Clinical Utility of CAC in CKD
CAC is being used as a screening test to assess risk of future CV events in patients without CKD who are at intermediate CV risk because it may add to the prognostic utility of the Framingham Risk Score (52, 53) . Asymptomatic persons without CKD and without CAC have a very low risk of CV events, whereas those with scores .400 AU have elevated risk similar to that in patients with diabetes or peripheral vascular disease (54) . Studies in patients without CKD reported a strong correlation between CAC and total atherosclerotic plaque burden at the individual level (r=0.90) (55) . Although current guidelines do not recommend the routine use of CAC for risk stratification, they do recommend its use to inform treatment decision-making in patients without CKD if a risk-based treatment decision is uncertain after quantitative risk assessment using traditional CV risk factors (56) . However, it is too early to recommend the standard use of CAC for risk stratification in patients with CKD because it remains unclear whether such calcific lesions in a coronary artery segment increase or decrease biomechanical stability of atherosclerotic plaques in CKD (57) . Similarly, it is not known whether increased CAC or its progression truly plays a mechanistic role in the development of future CV events or is merely a surrogate for other CV risk factors in patients with CKD. Finally, there are not enough data to show that CAC is a modifiable risk factor in CKD. For example, it is not known whether the reduction of calcium or phosphate using various binders persistently influences regression of CAC in CKD or whether CAC regression translates to improved outcomes (58).
LV Mass or LV Dysfunction in CKD
LVH and abnormal LV function, based on echocardiographic parameters, are highly prevalent among patients with CKD who initiate dialysis. According to a Canadian cohort, 74% have LVH, 36% have LV dilation, and 15% have LVSD (59) . Higher baseline LVMI is associated with severity of CKD as well as progression, but it is not clear whether this is independent of high BP.
In a cross-sectional study of diabetic patients, severity of CKD stage paralleled increases in LVMI and decreases in LV ejection fraction (LVEF) (Table 4) (60). Patients with CKD stages 3-5 and LVH had lower eGFR and greater proteinuria than patients without LVH, as well as a weak inverse correlation between LVMI and eGFR (61). However, in multivariable models that included systolic BP and body mass index, eGFR was not independently associated with LVH (61) . Another cross-sectional study did report a correlation between urinary protein-to-creatinine ratio and LVMI, independent of systolic BP, although a similar correlation was not observed with eGFR (62) . These studies were limited by lack of controls without CKD. Interestingly, there were higher LV mass and greater degree of LVDD, but no difference in LVEF, among patients with CKD compared with age-and sex-matched controls according to univariate analyses (63) . However, pulse pressure was significantly higher in patients with CKD than in controls, which could account for the observed differences (63) . Finally, three prospective longitudinal studies reported changes in LV geometry to independently correlate with eGFR decline and progression to ESRD (Table 4 ) (64-66).
LV Mass, LV Dysfunction, and Clinical Outcomes
LVMI was independently associated with increased allcause and CV mortality in patients initiating dialysis in a prospective study, even after adjustment for age, CAD, diabetes mellitus, and systolic BP (59) . These findings were extended to outpatients with CKD stages 3-5, in whom higher LVMI and LVEF ,55% versus $55% at baseline were associated with CV events, including death, AMI, sustained ventricular arrhythmia, hospitalization for unstable angina, congestive heart failure, transient ischemic attack, or stroke at 26 months (Table 4) (67) .
Clinical Utility of LV Mass or LV Dysfunction in CKD
Although these data suggest that LVH is associated with CKD progression and CV events, elevated SBP and pulse pressure, which are highly prevalent in this patient population, may be major confounders in these analyses. In addition, lack of well controlled prospective studies limit the utility of echocardiographic parameters in predicting outcomes in clinical practice. Future studies need to analyze how changes in LV mass and function may be used to prognosticate hard clinical outcomes.
cIMT in CKD
The cIMT has become a frequently studied sonographic marker of early atherosclerotic changes in vessels. The thickening of the intima-media complex not only reflects a local vessel change in the carotid but could indicate a systemic change in all vessel walls. It may also predict future risk for CV events. The ease and safety of this imaging study allow its use as a potential new biomarker for systemic atherosclerosis in high-risk patient populations, such as predialysis patients with CKD. Several studies, mostly cross-sectional, suggested that cIMT measurements were elevated in CKD individuals, as reviewed later in this article (Table 5) .
In a case-control study, case-patients with a serum creatinine $0.40 mmol/L had significantly higher cIMT than controls (Table 5 ) (68) . Among patients with CKD stages 3-5, cIMT measurements were significantly higher if eGFR was ,60 ml/min per 1.73 m 2 than .60 ml/min per 1.73 m 2 (69) . Another study reported a weak but statistically significant correlation between lower eGFR and MESA, Multi-Ethnic Study of Atherosclerosis; cMRI, cardiac magnetic resonance imaging; cLVH, concentric LVH; aHR, adjusted hazard ratio; 95% CI, confidence interval; aOR, adjusted odds ratio; eGFR cr , eGFR calculated using serum creatinine; eGFR cys , eGFR calculated using cystatin C. higher mean maximum wall thickness measured along 12 carotid segments, after adjustment for age and sex (70) . Two studies revealed small but statistically significant stepwise increases in cIMT measurements with higher CKD stages (Table 5 ) (71, 72) .
cIMT and Clinical Outcomes
There are conflicting data on whether cIMT is associated with death or CV events in predialysis patients with CKD. A Chinese study of 203 patients with stages 3 or 4 CKD reported a statistically significant trend for higher adverse CV events for increasing cIMT quartiles (Table 5 ) (73) . In a longitudinal study of 3364 outpatients with and without CKD, lower creatinine clearance and higher cIMT were associated with fatal and nonfatal vascular events (74) . However, in a study of nondiabetic outpatients with eGFR,60 ml/min per 1.73 m 2 , carotid plaque burden but not cIMT was associated with fatal or nonfatal acute coronary syndrome (ACS) or stroke (75) . Similarly, Marcos et al. did not show a significant association between the severity of cIMT and CV events or death (76) . cIMT could not be used to reliably discriminate prevalent CVD in a group of outpatients with CKD (77) . Finally, a recent analysis of the Multi-Ethnic Study of Atherosclerosis cohort revealed that CAC was superior to cIMT for CVD prediction in patients with and those without CKD (Table 5 ) (78) .
Clinical Utility of cIMT in CKD
Although studies suggested that cIMT measurements are higher in patients with CKD than in those without CKD, the differences were small and of unclear clinical relevance. In addition, observed increases in cIMT with decreasing eGFR or advancing CKD stages could be confounded by other traditional risk factors that cause CKD progression, such as uncontrolled hypertension or diabetes. At present, cIMT has not proven to be a reliable predictor of hard outcomes in predialysis patients with CKD. Currently, the standardization of cIMT measurement is a major challenge, and it is not routinely recommended in clinical practice for risk assessment in the general population, let alone patients with CKD (56) . Further research needs to delineate whether cIMT can be reliably measured in patients with CKD and used as a screening test for CV risk stratification in this patient population.
Conclusion
In summary, Figure 3 outlines the potential uses of an ideal circulating and imaging cardiac biomarker, which should be similar in patients with predialysis CKD. However, given current knowledge gaps, more data need to become available before all of these markers can be reliably used in this patient population. Observational studies reporting associations between cTnT and NT-pro-BNP and decline in eGFR in nondialysis patients with CKD may be confounded by decreased renal clearance of these biomarkers in the setting of advanced CKD. The same traditional and nontraditional factors associated with CAC are likely also correlated with CKD progression. Although the evidence presented suggests that these biomarkers may be used to predict future CV events in asymptomatic patients with CKD, future studies need to confirm reliable cutoffs for the utility of these biomarkers as diagnostic tests in patients presenting with symptoms concerning for ACS or acute CHF. In addition, it remains unclear whether cardiac biomarkers such as cTnT, NT-pro-BNP, BNP, CAC, and cIMT in asymptomatic patients with CKD are modifiable and amenable to interventions to reduce future CV risk. Further studies are needed to inform whether better risk stratification scores that include novel in addition to traditional biomarkers should be developed to quantify CV risk in patients with CKD. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association, the National Institutes of Health, or the Department of Veterans Affairs.
